88790-37-8

Basic information

• Product Name: METHYL (2S)-PYRROLIDIN-2-YLACETATE
• Synonyms: (S)-METHYL 2-(PYRROLIDIN-2-YL)ACETATE;(S)-tert-butyl 2-(2-methoxy-2-oxoethyl)pyrrolidine-1-carboxylate
• CAS NO: 88790-37-8
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.301
• Mol File: 88790-37-8.mol

Chemical Properties

• Boiling Point: 190.215 °C at 760 mmHg
• Flash Point: 68.84 °C
• Appearance: /
• Density: 1.006 g/cm³
• Vapor Pressure: 0.548mmHg at 25°C
• Refractive Index: 1.44
• PKA: -2.51±0.40(Predicted)
• CAS DataBase Reference: METHYL (2S)-PYRROLIDIN-2-YLACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL (2S)-PYRROLIDIN-2-YLACETATE(88790-37-8)
• EPA Substance Registry System: METHYL (2S)-PYRROLIDIN-2-YLACETATE(88790-37-8)

Safety Data

• Hazardous Substances Data: 88790-37-8(Hazardous Substances Data)

Usage

Uses

Used in Flavor and Fragrance Industry:
METHYL (2S)-PYRROLIDIN-2-YLACETATE is used as a flavor and fragrance ingredient for its distinctive fruity and floral scent with a sweet, caramel-like undertone. It is incorporated into the production of perfumes, cosmetics, and food products to enhance their aroma and appeal to consumers.
Used in Pharmaceutical Industry:
METHYL (2S)-PYRROLIDIN-2-YLACETATE is used in the pharmaceutical industry for its potential therapeutic properties. It has been studied for its anti-inflammatory and anti-aging effects, making it a promising candidate for the development of new medications and treatments.
Safety:
METHYL (2S)-PYRROLIDIN-2-YLACETATE is considered safe for use in approved applications and has been deemed generally recognized as safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA). This designation indicates that the compound has undergone a thorough safety evaluation and is deemed safe for use in the specified applications.

InChI:InChI=1/C7H13NO2/c1-10-7(9)5-6-3-2-4-8-6/h6,8H,2-5H2,1H3/t6-/m0/s1

Upstream product

• 186581-53-3 diazomethane 
• 34619-03-9 tert-butyldicarbonate 
• 147-85-3 L-proline 
• 67-56-1 methanol 
• 101130-03-4 tert-butyl (S)-2-(diazoacetyl)pyrrolidine-1-carboxylate 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 84890-94-8 (S)-2-Isobutoxycarbonyloxycarbonyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 223118-68-1 tert-butyl (E)-2-(2-methoxy-2-oxoethylidene)pyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 56502-01-3 (2S)-1-tert-butoxycarbonyl-2-carboxymethylpyrrolidine 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 259868-83-2 (S)-pyrrolidin-2-ylacetic acid methyl ester hydrochloride 
• 86971-65-5 pyrrolidin-2-ylidene-acetic acid methyl ester 
• 141874-26-2 N-Boc-(S)-proline chloride 

Downstream Products

• 61810-78-4 (-)-2-((S)-1-methylpyrrolidin-2-yl)ethanol 
• 88790-38-9 (2S)-tert-butyl 2-(2-hydroxyethyl)pyrrolidine-1-carboxylate 
• 53912-83-7 [(2S)-pyrrolidin-2-yl]acetic acid methyl ester 
• 191528-63-9 [(S)-1-(2-Azido-benzoyl)-pyrrolidin-2-yl]-acetaldehyde 
• 191528-62-8 (2-Azido-phenyl)-[(S)-2-(2-hydroxy-ethyl)-pyrrolidin-1-yl]-methanone 
• 191528-61-7 Carbonic acid 2-[(S)-1-(2-azido-benzoyl)-pyrrolidin-2-yl]-ethyl ester methyl ester 
• 526-64-7 laburnine 
• 1338968-17-4 C₂₉H₄₁NO₃ 
• 1178977-16-6 (S)-1,1-bis(4-propylphenyl)-2-(pyrrolidin-2-yl)ethanol 
• 1338968-19-6 C₃₃H₄₉NO₃ 
• 1178977-17-7 (S)-1,1-bis(4-pentylphenyl)-2-(pyrrolidin-2-yl)ethanol 
• 1338968-20-9 C₂₇H₂₅F₁₂NO₃ 
• 1178977-14-4 (S)-1,1-bis(3,5-bis(trifluoromethyl)phenyl)-2-(pyrrolidin-2-yl)ethanol 
• 1178977-11-1 (S)-1,1-diphenyl-2-(pyrrolidin-2-yl)ethanol 

Relevant articles and documents

Tetrahydropyrido [3, 4-d] pyrimidine derivative and medical application thereof

The invention relates to a compound as shown in a general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate and a preparation method thereof, and application of the compound in preparation of drugs for treating diseases related to KRas-G12C activity or expression quantity.

Iminium ion-enamine cascade cyclizations: Facile access to structurally diverse azacyclic compounds and natural products

A one-pot, mild, two-component iminium ion-enamine cascade reaction to construct structurally diverse azacyclic frameworks from l-proline and l-pipecolic acid, and its application to indolizidine and quinolizidine alkaloids and azasteroids, is reported.

Kinetic deconjugation: A gateway to the synthesis of Xxx-Gly (E)-alkene dipeptide isosteres

A new method for the preparation of Xxx-Gly (E)-alkene dipeptide isosteres (EADIs), using LDA deprotonation followed by 1 N HCl quench, was explored. The method, named kinetic deconjugation, enabled the synthesis of Tyr-Gly, Gly-Gly, Ser-Gly, Pro-Gly, and

A systematic study of chiral homoprolinols and their derivatives in the catalysis of enantioselective addition of diethylzinc to aldehydes

Homoprolinol analogs, a class of optically active γ-amino alcohols, were examined systematically in the enantioselective addition reactions of diethylzinc to aldehydes. By comparison of the results catalyzed by these γ-amino alcohols with those by the β-amino alcohols based on pyrrolidine architecture reported in the literature references, we have observed that the γ-amino alcohols are superior to the corresponding β-amino alcohols when the nitrogen and the oxygen are unsubstituted. Among the homoprolinols we tested, 2b gave the best results (45-88% yields, 44-81% ee) in the addition reactions. To the best of our knowledge, 2b has been noticed as one of the most efficient γ-amino alcohol catalysts based on pyrrolidine framework.

Asymmetric synthesis of homoproline derivatives via Rh(I)-catalyzed hydrogenation using chiral bisphosphines as ligands

It has been demonstrated for the first time that Rh(I)-catalyzed asymmetric hydrogenation of cyclic β-enamino acid derivatives 1 using chiral bisphosphines could be a highly efficient synthetic method for optically active homoproline derivatives. The enantioselectivity and conversion yield were largely dependent upon the chiral ligand. Using the Me-BDPMI forming a seven-membered metal chelate, the N-acetylated β-enamino acid methyl ester 1a was hydrogenated to give optically active homoproline derivative 2a with 100% conversion and 96% ee.

CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS

The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions which are related to irregular calcification.

Studies towards the preparation of sparteine-like diamines for asymmetric synthesis

A route for the preparation of sparteine-like diamines starting from naturally occurring amino acids has been explored. Starting from the amino acids (S)-proline and (S)-phenylalanine, two novel sparteine-like diamines 2 and 3 have been prepared. The synthetic route involves Dieckmann condensation followed by a double Mannich reaction to set up the tricyclic structure with control of the relative stereochemistry. During the Dieckmann and Mannich reactions it was found that racemisation occurred either via retro-Michael or retro-Mannich processes. Conditions for preventing racemisation in the Dieckmann reaction were uncovered but it was not possible to prevent racemisation during the double Mannich reaction. Thus, the two novel sparteine-like diamines 2 and 3 have been prepared in racemic form. The Royal Society of Chemistry 1999.

Investigation of the 4-O-alkylamine substituent of non-peptide quinolone GnRH receptor antagonists

Synthesis and in vitro activity of the enantiomers of quinolone GnRH antagonist (±)-1 are reported. Chiral amino alcohols were prepared from the appropriate cyclic D- or L-amino acids by the Arndt-Eistert homologation followed by reduction of the resulting esters. Incorporation of these pharmacophores was achieved via a novel Mitsunobu alkylation of 4-hydroxyquinolones. The key amine pharmacophore for binding to the rat GnRH receptor was most active in the S-configuration. Ring size was not important for potency with 4, 5, 6, and 7-membered ring amines exhibiting similar potency.

Diastereoselective synthesis of (-)-1-methyl-(3S,4R)-3,4-bis((2S)-N- (tert-butyloxycarbonyl)pyrrolidin-2-yl)-2-pyrrolidinone by an asymmetric Michael reaction

Beginning with enantiomerically pure L-proline, (-)-1-methyl-(3S,4R)- 3,4-bis((2S)-N-(tert-butyloxycarbonyl)pyrrolidin-2-yl)-2-pyrrolidinone was prepared in diastereomerically pure form. Taking advantage of the chiral induction of the L-proline derivatives, the intermolecular Michael reaction, used to build the pyrrolidinone ring, was carried out stereoselectively.

The synthesis of a novel benzodiazocine via an intramolecular Staudinger/aza-Wittig cyclization

The novel pyrrolobenzodiazocine (1) has been prepared by an intramolecular Staudinger/aza Wittig protocol from the precursor azido aldehyde (2) in a remarkable 93% yield. Aldehyde (2) was prepared by coupling protected homoprolinol with 2-azidobenzoic aci